A new study from the laboratory of member researcher John Stagg, first authored by Bertrand Allard, sheds new light on a previously unknown role of the A2A adenosine receptor in cancer. A2A normally allows tumor cells to escape elimination by immune cells.

However, the recent findings published today in Cell Reports Medicine indicates that the anti-inflammatory and anti-obesogenic functions of A2A restrict the development of liver cancer in mice. This new finding suggests caution in the use of pharmacological A2A inhibitors in patients.

To read the full scientific article, click here.